Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights

Core Insights - Sofwave Medical Ltd reported record quarterly revenue of $21.1 million for Q3 2025, reflecting a 56% year-over-year growth, with a gross margin of 73.7% [1][5][6] - The company achieved a recurring revenue of $8.3 million in Q3 2025, marking a 55% increase year-over-year, which constitutes 40% of total revenue [1][5] - For the first nine months of 2025, Sofwave's revenue reached $58.7 million, a 42% year-over-year growth, with a gross margin of 75.1% [1][5][6] - Sofwave reported a net income of $1.4 million for the first nine months of 2025, a significant turnaround from a net loss of $3.8 million in the same period of the previous year [1][5][6] - The company has administered approximately 667,000 pulse treatments since commercialization and anticipates achieving net profitability by 2025 [1][8] Financial Highlights - Q3 2025 revenue was $21.1 million, up from $13.5 million in Q3 2024, with a gross profit of $15.5 million, a 53% increase year-over-year [5][6] - The first nine months of 2025 saw revenues of $58.7 million compared to $41.3 million in the same period of 2024, with a gross profit of $44.1 million, reflecting a 41% increase [5][6] - Positive cash flow of $2.5 million was generated in Q3 2025, compared to $0.2 million in the corresponding period of the previous year [5][6] Management Commentary - The CEO of Sofwave highlighted the exceptional performance in Q3 2025, driven by over 50% year-over-year growth in both capital equipment placements and recurring revenue, indicating strong demand from customers [4] - The Chairman emphasized the record revenue as a testament to the company's disruptive technology and the shift in the aesthetic market towards next-generation treatment solutions [4] - The company is positioned to expand further in the non-invasive medical aesthetics space, driven by the growing adoption of GLP-1 treatments [4]